Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April
Vaxxinity CEO Mei Mei Hu to participate in fireside chat with Sarah Despres, Counselor to the Secretary for Public Health and Science, U.S. Department of Health and Human Services, at World Vaccine Congress
UB-313 to be Featured in Emerging Science Presentation at AAN Annual Meeting
CAPE CANAVERAL, Fla., March 28, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that members of its leadership team will present data on investigational vaccines for COVID-19 and neurodegenerative diseases at three upcoming scientific and medical conferences in April.
World Vaccine Congress (April 3-6, 2023)
Presentation Date & Time: April 6, 2023, 10:10 a.m. EDT
Presentation Date & Time: April 6, 2023, 12:00 p.m. EDT
AAN Annual Meeting (April 22-27, 2023)
Speakers: Jean-Cosme Dodart, Ph.D., Senior Vice President, Research at Vaxxinity; Hui Jing Yu, Ph.D., Senior Director, Clinical Development at Vaxxinity
British Neuroscience Association 2023 Festival of Neuroscience (April 23-26, 2023)
For more information about Vaxxinity, Inc., visit http://www.vaxxinity.com and follow us on social media @vaxxinity.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "potentially," and "will" and similar expressions, are intended to identify forward-looking statements. These forward-looking statements involve substantial risks and uncertainties, and are based on the current expectations and assumptions of Vaxxinity’s management. Forward-looking statements include statements about the development of a new class of immunotherapeutic vaccines and the innovation and efficacy of Vaxxinity’s product candidates. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements. Additional important factors to be considered in connection with forward-looking statements are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 27, 2023 and other reports we file with the Securities and Exchange Commission. The forward-looking statements are made as of this date and Vaxxinity does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.